Transgene Biotek Ltd Financial Ratios
TRANSGENEBIOTEKLTD · Healthcare Services · Current price
P/E ratio
—
P/B ratio
2.8x
ROE
-17.9%
ROCE
-2.4%
Debt / Equity
2.05
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | — | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 2.8x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | -17.9% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | -2.4% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 2.05 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Transgene Biotek Ltd's latest numbers.
Transgene Biotek Ltd profitability
Transgene Biotek Ltd generates a return on equity of -17.9% and a return on capital employed of -2.4%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 2.05 and a P/E of —, Transgene Biotek Ltd is carrying meaningful debt. Our overall business-quality score for the company is 1.4 / 10.
Understand the ratios
More on Transgene Biotek Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.